Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Northland Capital Partners View on the City Keras Resources and SalvaRx Group

Keras Resources (LON:KRS) – CORP*: Mining underway

Market Cap: £12m; Current Price: 1p

Commences mining under bulk sample permit at Anomaly 22

Keras Resources has commenced mining under the bulk sample permit bulk at the Anomaly 22 target, located in the Grants Patch Gold Tribute Project.

The extracted ore will be initially stockpiled before being trucked to the Paddington mill early next week.

SalvaRx Group plc (LON:SALV): First day of dealings

First day of dealings, Northland Capital Partners acts as Nomad and Broker

SalvaRx (formerly known as 3Legs Resources plc), a biotech company focused on therapies that leverage the immune system to fight cancer, announced the commencement at 8.00 a.m. today of dealings in its Ordinary Shares on the AIM market of the London Stock Exchange following the reverse takeover of SalvaRx Limited.

Northland Capital Partners acts as Nominated Adviser and Broker to the Company.

Immunotherapy is a fast growing and new therapeutic area within oncology, which is expected to grow to $80 billion worldwide by 2020, and seeks to use a patient's own immune system to fight cancer, either by stimulating the existing immune system or by the administration of man-made immune system proteins.

SalvaRx's strategy is to acquire and invest in a portfolio of companies involved in novel cancer immunotherapies.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK